Jack Luke Janetzki (Jack L Janetzki)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Chronic Obstructive Pulmonary Disease

Top Venues

Administration and policy in mental health

Journal of clinical pharmacy and therapeutics

British journal of clinical pharmacology

The International journal of pharmacy practice

This page only lists publications with an associated author ORCID identifier.

Publications

Lisa Kalisch Ellett, Jack Luke Janetzki, Renly Lim, Tracey-Lea Laba, Nicole L Pratt
Innovations in pharmacovigilance studies of medicines in older people. British journal of clinical pharmacology (2024)
Tien Ngoc Thi Bui, Ruby Tszwai Au, Jack Luke Janetzki, Sara Sinclair McMillan, Elizabeth Hotham, Vijayaprakash Suppiah
Metabolic Monitoring for Adults Living with a Serious Mental Illness on a Second-Generation Antipsychotic Agent: A Scoping Review. Administration and policy in mental health (2024)
Tien Ngoc Thi Bui, Jack Luke Janetzki, Wern Chern Chai, Vijayaprakash Suppiah
Exploring consumers' perspective of community pharmacists delivering COVID-19 vaccinations: an Australian pilot study. The International journal of pharmacy practice (2023)
Jack Luke Janetzki, Nicole L Pratt, Michael B Ward, Matthew J Sykes
Application of an Integrative Drug Safety Model for Detection of Adverse Drug Events Associated With Inhibition of Glutathione Peroxidase 1 in Chronic Obstructive Pulmonary Disease. Pharmaceutical research (2023)
Jack Luke Janetzki, Matthew J Sykes, Michael B Ward, Nicole L Pratt
Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis. Drug safety (2023)
Jack Luke Janetzki, Matthew J Sykes, Michael B Ward, Nicole L Pratt
Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-A sequence symmetry analysis approach. Journal of clinical pharmacy and therapeutics 46 (6) (2021)